Medicines Ban – Centre Prohibits 16 Drug Combinations Over Safety Concerns
Medicines Ban – The Central Government has ordered an immediate nationwide ban on the manufacture, sale, distribution and supply of 16 fixed-dose combination (FDC) medicines after determining that these products do not offer sufficient medical benefits and may expose patients to unnecessary health risks.
The decision was announced by the Union Health Ministry as part of ongoing efforts to improve patient safety and encourage the responsible use of medicines across the country. Officials stated that only treatments backed by scientific evidence and proven therapeutic value should remain available in the market.
Review Conducted Under Expert Supervision
Fixed-dose combination medicines contain two or more active pharmaceutical ingredients combined in predetermined proportions. According to the ministry, the latest action follows a detailed examination of such formulations carried out in accordance with directions issued by the Supreme Court.
To evaluate the safety and effectiveness of these medicines, the Drugs Technical Advisory Board (DTAB) formed a specialist committee. The panel reviewed numerous drug combinations to identify products that were medically unjustified, lacked proven effectiveness, or had the potential to cause harm.
Following the committee’s findings, authorities concluded that 16 specific formulations failed to meet acceptable therapeutic standards and should no longer be available for human use.
Wide Range of Products Included
The prohibited medicines belong to several treatment categories, including pain-relief products, muscle-relaxant formulations, antibiotic combinations and certain skincare preparations.
Among the combinations affected by the ban are Acetyl Salicylic Acid with Ethoheptazine; Dicyclomine, Paracetamol and Clidinium Bromide; Dicyclomine, Paracetamol, Clidinium Bromide and Chlordiazepoxide; Gliclazide with Chromium Picolinate; and Paracetamol combined with Lignocaine.
Health authorities noted that these formulations did not demonstrate adequate therapeutic value when compared with the potential risks associated with their use.
Several Antibiotic Combinations Removed
A number of antibiotic-based medicines have also been barred from the market. These include combinations involving Amoxicillin with Serratiopeptidase, Amoxicillin with Serratiopeptidase and Lactobacillus Sporogenes, as well as formulations containing Amoxicillin, Cloxacillin, Lactic Acid Bacillus and Serratiopeptidase.
Other prohibited products include Cefadroxyl with Probenecid and Cefuroxime with Serratiopeptidase. Experts have repeatedly stressed the importance of prescribing antibiotics rationally to reduce unnecessary exposure and support better treatment outcomes.
Certain Dermatology Products Also Affected
The ban extends to several dermatological and skincare formulations that combine Aloe Vera or Aloe Extract with ingredients such as Vitamin E, Jojoba Oil, Orange Oil, Wheat Germ Oil, Tea Tree Oil, Allantoin and D-Panthenol.
According to the ministry, these products were among those identified during the scientific review process as lacking sufficient justification for continued use.
Government Emphasises Rational Medicine Use
The prohibition has been enforced through notifications issued under Section 26A of the Drugs and Cosmetics Act, 1940. The ministry said the measure forms part of a broader strategy to strengthen medicine regulation and protect consumers from treatments that do not provide established clinical benefits.
Officials also pointed out that similar actions have been taken in previous years after extensive scientific assessments of irrational drug combinations.
State drug regulators, enforcement agencies and drug control authorities have been instructed to ensure strict implementation of the latest notifications. Manufacturers, importers and distributors have likewise been directed to take all necessary steps to comply with the revised regulations without delay.